MX2021012409A - Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular. - Google Patents

Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.

Info

Publication number
MX2021012409A
MX2021012409A MX2021012409A MX2021012409A MX2021012409A MX 2021012409 A MX2021012409 A MX 2021012409A MX 2021012409 A MX2021012409 A MX 2021012409A MX 2021012409 A MX2021012409 A MX 2021012409A MX 2021012409 A MX2021012409 A MX 2021012409A
Authority
MX
Mexico
Prior art keywords
materials
methods
gender
cardiovascular dysfunction
dependent treatment
Prior art date
Application number
MX2021012409A
Other languages
English (en)
Spanish (es)
Inventor
Bin Zhang
Jordan D Miller
Maurice E Enriquez-Sarano
Carolyn Marie Roos
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021012409A publication Critical patent/MX2021012409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021012409A 2019-04-10 2020-04-10 Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular. MX2021012409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832139P 2019-04-10 2019-04-10
PCT/US2020/027777 WO2020210707A1 (en) 2019-04-10 2020-04-10 Methods and materials for gender-dependent treatment of cardiovascular dysfunction

Publications (1)

Publication Number Publication Date
MX2021012409A true MX2021012409A (es) 2021-11-12

Family

ID=72752121

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012409A MX2021012409A (es) 2019-04-10 2020-04-10 Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
MX2024010759A MX2024010759A (es) 2019-04-10 2021-10-08 Materiales y sus usos para el tratamiento dependiente del genero de la disfuncion cardiovascular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010759A MX2024010759A (es) 2019-04-10 2021-10-08 Materiales y sus usos para el tratamiento dependiente del genero de la disfuncion cardiovascular.

Country Status (11)

Country Link
US (1) US12465605B2 (https=)
EP (1) EP3952992A4 (https=)
JP (2) JP2022526621A (https=)
KR (1) KR20210150495A (https=)
CN (1) CN114144229A (https=)
AU (2) AU2020273183A1 (https=)
CA (1) CA3136550A1 (https=)
IL (1) IL287073A (https=)
MX (2) MX2021012409A (https=)
SG (1) SG11202110533RA (https=)
WO (1) WO2020210707A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357506A (zh) * 2023-09-11 2024-01-09 重庆医科大学国际体外诊断研究院 丹酚酸a在治疗钙化性主动脉瓣膜疾病中的用途
CN117969836B (zh) * 2024-03-29 2024-06-04 北京市心肺血管疾病研究所 基于血浆炎症蛋白构建主动脉瓣钙化狭窄诊断模型及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR22934E (fr) 1919-07-19 1921-09-06 Albert Jean Baptiste Hanotelle Sifflet électro-automoteur perfectionné pour répétition des signaux sur la locomotive
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
US6723719B1 (en) 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
AU755361B2 (en) 1998-02-19 2002-12-12 Eisai R&D Management Co., Ltd. Phthalazine derivatives and remedies for erectile dysfunction
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6774128B2 (en) 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
JP2004501124A (ja) 2000-06-07 2004-01-15 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 化合物
US6911542B2 (en) 2000-06-23 2005-06-28 Lilly Icos Llc. Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives
MXPA02012470A (es) 2000-06-23 2004-01-26 Lilly Icos Llc Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MXPA02012659A (es) 2000-06-26 2003-09-22 Lilly Icos Llc Derivados de pirazindiona condensados.
DE60121461T2 (de) 2000-10-03 2007-02-08 Lilly Icos Llc, Wilmington Kondensierte pyridoindolderivate
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
WO2003101276A2 (en) 2002-05-22 2003-12-11 Virginia Commonwealth University Protective effects of pde-5 inhibitors
AU2003286555A1 (en) 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
GB0318094D0 (en) 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
WO2007050585A2 (en) 2005-10-24 2007-05-03 The Johns Hopkins University Use of a nitric oxide synthase modulator for the treatment of cardiac indications
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
CA2720343A1 (en) * 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
GB201114901D0 (en) 2011-08-26 2011-10-12 King S College London Vascular treatments
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
AU2014305843B2 (en) * 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
MX2017014057A (es) * 2015-05-06 2018-04-10 Bayer Pharma AG El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de ulceras digitales (du) concomitante con esclerosis sistemica (ssc).
US11202760B2 (en) * 2016-09-30 2021-12-21 Xenamed Corp. Compositions of midodrine and methods of using the same
MX2019006938A (es) * 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Also Published As

Publication number Publication date
SG11202110533RA (en) 2021-10-28
MX2024010759A (es) 2024-09-10
WO2020210707A1 (en) 2020-10-15
EP3952992A4 (en) 2023-04-19
JP2025172729A (ja) 2025-11-26
AU2025256169A1 (en) 2025-11-13
JP2022526621A (ja) 2022-05-25
AU2020273183A1 (en) 2021-10-14
KR20210150495A (ko) 2021-12-10
US12465605B2 (en) 2025-11-11
US20220211702A1 (en) 2022-07-07
EP3952992A1 (en) 2022-02-16
IL287073A (en) 2021-12-01
CN114144229A (zh) 2022-03-04
CA3136550A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
CL2021001366A1 (es) Anticuerpos humanizados contra c-kit
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EP3873357C0 (en) DEVICES FOR TREATMENT OF CALCIFIED HEART VALVES
CO2020009625A2 (es) Inhibidor de fap
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
AR113490A1 (es) CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
EP3496625C0 (en) PROSTHETIC HEART CAVITY VALVE IMPLANT WITH HIGH VALVE SECTION AND SINGLE CHAMBER ANCHOR FOR PRESERVATION, SUPPLEMENTATION AND/OR REPLACEMENT OF ORIGINAL VALVE FUNCTION
MX2019003251A (es) Dispositivos y metodos de stent vascular.
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
AR101462A1 (es) Composiciones de esporas bacterianas para uso industrial
CR20130395A (es) Endoprótesis Vascular de Extremos Romos para Válvula Cardiaca Prostética
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
EP3946162A4 (en) HEART VALVE PROSTHESIS
MX2021012409A (es) Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
MX387804B (es) Metodos para tratar presion intraocular con activadores de tie-2
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2016012248A (es) Composiciones para el tratamiento de autodigestion.
MX2016015635A (es) Metodos y composiciones para evitar la lesion por isquemia-reperfusion en organos.
BR112018074820A2 (pt) surfactantes não iónicos para a redução de tecido adiposo
MX2018016055A (es) Células que expresan receptor de hormona paratiroidea 1 y usos de las mismas.
CL2022001459A1 (es) Célula vector adyuvante artificial con contenido de ny-eso-1 para el tratamiento del cancer